AlloMend Acellular Dermal Matrix Allograft in Pre-Pectoral Breast Reconstruction

Conditions

• Pre-Pectoral Breast Reconstruction Following Single or Double Mastectomy

Eligibility Criteria

Sex

FEMALE

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• AlloMend® Acellular Dermal Matrix allograft — OTHER
  AlloSource, a non-profit supplier of allografts and one of the nation's leading tissue banks, introduced AlloMend® Acellular Dermal Matrix allograft to bring the benefits of regenerative medicine to more patients. cellular allograft matrices, unlike synthetic materials or xenografts, are recognized as human tissue by the body for graft incorporation by the recipient, minimizing the risk of inflammation or rejection. AlloMend® Acellular Dermal Matrix allograft has been shown to incorporate into the surgical site and demonstrates blood vessel infiltration.

Study Details

This is a single-center, retrospective study which will be used to describe and evaluate the effectiveness of AlloMend® Acellular Dermal Matrix allograft for patients that have undergone Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.

Key Dates

Start date

Oct 19, 2023

Status verified

Nov 2025

Primary completion

Jun 30, 2026

Completion

Dec 31, 2026

Study Design

Enrollment

200 participants (estimated)

Primary Outcome Measure

Descriptive Data Collection [ Time Frame: Up to 6- months post-operatively ]

Central Contacts

• Elizabeth Esterl, DNP, MS, RN
  7207326231
  [email protected]
• Paige McHenry, MS, ATC, CCRA
  2154997062
  [email protected]

Locations (1)

Find similar trials in Joliet, IL